Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aerpio Pharmaceuticals (ARPO) shares

Learn how to easily invest in Aerpio Pharmaceuticals shares.

Aerpio Pharmaceuticals is a biotechnology business based in the US. Aerpio Pharmaceuticals stocks (ARPO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.76 – an increase of 0.59% over the previous week. Aerpio Pharmaceuticals employs 12 staff and has a market cap (total outstanding stock value) of $104.9 million.

How to buy stocks in Aerpio Pharmaceuticals

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARPO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Aerpio Pharmaceuticals stock price (NASDAQ:ARPO)

Use our graph to track the performance of ARPO stocks over time.

Aerpio Pharmaceuticals shares at a glance

Information last updated 2021-10-31.
Latest market close$1.70
52-week range$1.62 - $30.00
50-day moving average $31.63
200-day moving average $25.85
Wall St. target price$22.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.41

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get $500 in commission free trades when you fund your account with a minimum of $10,000. Conditions apply. Ends August 31st, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Aerpio Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Aerpio Pharmaceuticals price performance over time

Historical closes compared with the close of $1.7 from 2021-05-28

1 week (2022-05-13) N/A
1 month (2022-04-20) N/A
3 months (2022-02-20) N/A
6 months (2021-11-20) N/A
1 year (2021-05-24) -2.30%
2 years (2020-05-22) 117.95%
3 years (2019-05-24) 58.14%
5 years (2017-05-20) N/A

Aerpio Pharmaceuticals financials

Gross profit TTM $15 million
Return on assets TTM -31.02%
Return on equity TTM -47.61%
Profit margin 0%
Book value $0.74
Market capitalisation $104.9 million

TTM: trailing 12 months

Aerpio Pharmaceuticals share dividends

We're not expecting Aerpio Pharmaceuticals to pay a dividend over the next 12 months.

Aerpio Pharmaceuticals share price volatility

Over the last 12 months, Aerpio Pharmaceuticals's shares have ranged in value from as little as $1.62 up to $30. A popular way to gauge a stock's volatility is its "beta".

ARPO.US volatility(beta: 1.65)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aerpio Pharmaceuticals's is 1.6466. This would suggest that Aerpio Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Aerpio Pharmaceuticals overview

Aerpio Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site